ViiV la différence: VIKING-3 bolsters dolutegravir's case in multi-resistant HIV
This article was originally published in Scrip
Executive Summary
ViiV Healthcare has presented the first Phase III results for dolutegravir in HIV-1 patients resistant to multiple antiretroviral therapies including other integrase inhibitors, providing the first large-scale view of the molecule's efficacy in this challenging population.